| scholarly article | Q13442814 |
| P50 | author | Emmanuel S. Antonarakis | Q79135452 |
| P2093 | author name string | Daniel L Suzman | |
| P2860 | cites work | Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer | Q36301801 |
| Dual roles of PARP-1 promote cancer growth and progression | Q36460391 | ||
| Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study | Q36999978 | ||
| Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. | Q37963173 | ||
| Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases | Q38004275 | ||
| Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy | Q38458031 | ||
| Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. | Q38470336 | ||
| Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. | Q42928474 | ||
| Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells | Q43448621 | ||
| Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. | Q43670874 | ||
| Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). | Q44799712 | ||
| Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, B | Q50557822 | ||
| Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors | Q21245714 | ||
| Clusterin inhibits apoptosis by interacting with activated Bax | Q24316499 | ||
| Abiraterone in metastatic prostate cancer without previous chemotherapy | Q24612084 | ||
| Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment | Q24618224 | ||
| Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer | Q24632187 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy | Q26851608 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. | Q27852366 | ||
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Overcoming mutation-based resistance to antiandrogens with rational drug design | Q28044590 | ||
| Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study | Q28275476 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 | ||
| Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| Immunologic correlates of the abscopal effect in a patient with melanoma | Q29620334 | ||
| Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma | Q33386521 | ||
| Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen | Q33756662 | ||
| Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial | Q33946929 | ||
| High expression of the Met receptor in prostate cancer metastasis to bone | Q34163761 | ||
| Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer | Q34217642 | ||
| ARN-509: a novel antiandrogen for prostate cancer treatment | Q34248790 | ||
| CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer | Q34585720 | ||
| Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis | Q34720087 | ||
| Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. | Q34973214 | ||
| TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate | Q35256427 | ||
| Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th | Q35549709 | ||
| Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer | Q35967139 | ||
| P433 | issue | 4 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 167-179 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Therapeutic advances in medical oncology | Q26842113 |
| P1476 | title | Castration-resistant prostate cancer: latest evidence and therapeutic implications | |
| P478 | volume | 6 |
| Q38840506 | A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer. |
| Q38794127 | An integrated microfluidic chip for immunomagnetic detection and isolation of rare prostate cancer cells from blood |
| Q38568568 | Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer |
| Q26799813 | Androgen deprivation of prostate cancer: Leading to a therapeutic dead end |
| Q38865487 | Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. |
| Q26740070 | CYP17 inhibitors in prostate cancer: latest evidence and clinical potential |
| Q35641491 | Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer |
| Q40479406 | Clinical outcomes of anti-androgen withdrawal and subsequent alternative anti-androgen therapy for advanced prostate cancer following failure of initial maximum androgen blockade. |
| Q41070980 | Concurrent treatment with simvastatin and NF-κB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-κB/LIN28/let-7 miRNA signaling pathway. |
| Q92343354 | Development of a microfluidic platform for size-based hydrodynamic enrichment and PSMA-targeted immunomagnetic isolation of circulating tumour cells in prostate cancer |
| Q26748872 | Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review |
| Q28552864 | Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis? |
| Q38586459 | Emerging agents for the therapy of advanced prostate cancer |
| Q92941346 | Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells |
| Q37373117 | Geraniol suppresses prostate cancer growth through down-regulation of E2F8 |
| Q38667426 | Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial |
| Q48277880 | Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer |
| Q38942142 | Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy |
| Q38696205 | Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer |
| Q38785291 | Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region. |
| Q41022121 | NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence |
| Q50138454 | Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed? |
| Q37065079 | PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer |
| Q39222023 | Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases |
| Q38359237 | Prostate cancer vaccines: the long road to clinical application |
| Q85999688 | Prostate cancer: Clinical implications of therapeutic sequence in mCRPC |
| Q39001530 | Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety |
| Q92187418 | Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases |
| Q40975913 | Simultaneous inhibition of aryl hydrocarbon receptor (AhR) and Src abolishes androgen receptor signaling |
| Q37531813 | Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. |
| Q36502875 | Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report |
| Q38679991 | Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review |
Search more.